Nexpoint Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Nexpoint Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-282,592	Closed	-$10.9M	–	116
2023 Q2	$10.9M	Buy	+282,592	New	+$7.26M	1.58%	15

Nexpoint Asset Management's KDNY Position: Q3 2023 in Review

Nexpoint Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 282,592 shares — an estimated $10.9M sold.

Nexpoint Asset Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $10.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Nexpoint Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Nexpoint Asset Management sold 282,592 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $10.9M.
Nexpoint Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Nexpoint Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $10.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Nexpoint Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.